Alto Neuroscience, Inc. (ANRO) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Alto Neuroscience reported revenue of $0. Net income was -$63.2M, or -$2.19 per diluted share. Operating activities generated -$51.8M of cash, leaving -$51.8M of free cash flow. At fiscal year end, Alto Neuroscience held $184.7M in total assets against $33.5M in total liabilities, including $176.5M of cash and equivalents.
Open the full interactive Alto Neuroscience financials → Quarterly statements, key ratios, valuation history and price charts.
Alto Neuroscience Key Stats
| Share Price | $22.09 |
|---|---|
| Market Cap | $945.7M |
| 52-Week Range | $5.62 – $36.64 |
| Shares Outstanding | 42.8 million (basic, 2026 Q2) |
Alto Neuroscience Income Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Revenue | $0 | $0 |
| Operating Income | -$68.6M | -$66.4M |
| Pre-Tax Income | -$61.4M | -$63.2M |
| Income Tax | $0 | $0 |
| Net Income | -$61.4M | -$63.2M |
| Diluted EPS | -$2.50 | -$2.19 |
Alto Neuroscience Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$14.2M | -$16.2M | -$26.2M | -$27.6M |
| Diluted EPS | -$0.52 | -$0.56 | -$0.80 | -$0.65 |
Alto Neuroscience Balance Sheet
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash & Equivalents | $168.2M | $176.5M |
| Current Assets | $169.3M | $177.7M |
| Total Assets | $177.5M | $184.7M |
| Current Liabilities | $10.0M | $11.3M |
| Total Long-Term Debt | $10.3M | $16.8M |
| Total Liabilities | $26.1M | $33.5M |
| Shareholders' Equity | $151.5M | $151.1M |
Alto Neuroscience Cash Flow Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash From Operations | -$47.4M | -$51.8M |
| Cash From Investing | -$2.1M | -$24,000 |
| Cash From Financing | $135.7M | $60.1M |
| Free Cash Flow | -$49.5M | -$51.8M |
Figures from Alto Neuroscience's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Alto Neuroscience financials page for every line item.
Alto Neuroscience Company Profile
| Ticker | ANRO |
|---|---|
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Headquarters | Mountain View, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001999480 |
Frequently Asked Questions
What was Alto Neuroscience's revenue in fiscal 2025?
Alto Neuroscience (ANRO) reported revenue of $0 for fiscal 2025.
What was Alto Neuroscience's net income in fiscal 2025?
Alto Neuroscience reported net income of -$63.2M for fiscal 2025.
What was Alto Neuroscience's earnings per share (EPS) in fiscal 2025?
Alto Neuroscience's diluted EPS was -$2.19 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Alto Neuroscience generate in fiscal 2025?
Alto Neuroscience generated -$51.8M of free cash flow in fiscal 2025.
What was Alto Neuroscience's revenue last quarter?
In its most recent reported quarter (2026 Q2), Alto Neuroscience reported revenue of $0.
How much debt does Alto Neuroscience have?
Alto Neuroscience reported $16.8M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Alto Neuroscience are outstanding?
Alto Neuroscience reported a weighted average of 42.8 million basic shares outstanding in 2026 Q2.
What is Alto Neuroscience's market cap?
Based on its latest closing price, Alto Neuroscience (ANRO) has a market capitalization of about $945.7M.
When does Alto Neuroscience's fiscal year end?
Alto Neuroscience's fiscal year end, as registered with the SEC, is December 31.
Where is Alto Neuroscience headquartered?
Alto Neuroscience lists its business address in Mountain View, California in its SEC filings.